Amneal Pharmaceuticals (AMRX) Wins FDA Nod For Iohexol, Is The Upside Already Priced In?

Amneal Pharmaceuticals (AMRX) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for additional strengths and vial sizes of its iohexol injection, which expands its radiographic contrast agent offering.

See our latest analysis for Amneal Pharmaceuticals.

The FDA approval arrives at a time when Amneal Pharmaceuticals’ share price momentum is strong, with a 30 day share price return of 10.47% and a year to date share price return of 50.87%, alongside a 1 year total shareholder return of 136.68% that points to sustained investor interest over a longer period.

If this kind of move has your attention, it could be a good moment to widen your watchlist and check out 41 healthcare AI stocks

Amneal Pharmaceuticals now has a broader product mix and a share price that has moved sharply over the past year. The real question for investors is whether the current valuation still reflects a reasonable entry point.

Most Popular Narrative: 5% Overvalued

Analysts place Amneal Pharmaceuticals’ fair value at $18.25, which sits slightly below the last close at $19.10, so the current price already bakes in that narrative.

Strategic partnerships (such as with Metsera for GLP-1s and ApiJect for U.S. injectables), expansion into high-growth categories (GLP-1s, complex injectables, and biosimilars), and the upcoming launches in international markets (particularly India and Europe) provide new avenues for incremental revenue and profit growth in the coming years.

Read the complete narrative.

Curious what kind of revenue mix, margin lift, and future earnings multiple underpin that $18.25 fair value for Amneal Pharmaceuticals? The full narrative lays out the assumptions that make those numbers add up.

Result: Fair Value of $18.25 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still clear risks for Amneal Pharmaceuticals if U.S. generics pricing pressure persists or if key biosimilar and specialty launches face delays or tougher competition.

Find out about the key risks to this Amneal Pharmaceuticals narrative.

Another View on Amneal Pharmaceuticals: DCF vs Market Price

Analysts see Amneal Pharmaceuticals as about 5% overvalued against an $18.25 fair value, yet the Simply Wall St DCF model gives a very different signal. On that framework, the $19.10 share price sits around 64% below an estimated $53.36 fair value, which presents a much larger apparent valuation gap. The question for you is which set of assumptions feels more realistic.

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Amneal Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

Next Steps

With mixed signals on fair value and sentiment around Amneal Pharmaceuticals, it makes sense to move fast and review the underlying data yourself. To balance the enthusiasm with caution, start by weighing the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Amneal Pharmaceuticals?

If Amneal Pharmaceuticals has sharpened your focus on opportunities, do not stop here. Use the Simply Wall St Screener to compare other stocks and refine your watchlist.

Scan fresh possibilities, then line them up against screener containing 21 high quality undiscovered gems to spot companies with strong fundamentals that are not widely followed yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com